Literature DB >> 7808646

Leukotrienes and alpha tumor necrosis factor levels in the bronchoalveolar lavage fluid of patient at risk for the adult respiratory distress syndrome.

M Antonelli1, G Raponi, L Lenti, L Severi, O Capelli, L Riccioni, R A De Blasi, G Conti, C Mancini.   

Abstract

OBJECTIVE: To examine bronchoalveolar lavage (BAL) fluid of patients at risk for Adult Respiratory Distress Syndrome in the attempt to provide evidence of an increased local production of Leukotrienes (LTS) and Tumor Necrosis Factor (TNF).
DESIGN: Prospective, comparative, clinical study.
SETTING: ICU in a university hospital. PATIENTS: 14 patients at risk for ARDS and 10 control patients undergoing mechanical ventilation, were studied. INTERVENTION: BAL was performed in each patient at the time admission to the ICU (T0), and after 48 hours (T1).
RESULTS: Our controls never showed levels of TNF > 10 pg/ml and their LTS amounts were always below the detection limit. All patients at risk had levels of TNF ranging between 22 and 130 pg/ml, but no difference was noticed between patients who developed ARDS and those who did not, between survivors and non survivors, and between septic and non septic patients. LTD4 and LTB4 (ranging between 30 to 1365 pg/ml) were detected only in six of the 14 patients. Among these 6 patients, 4 developed ARDS. In these patients we could correlate LTB4 with TNF levels and the number of neutrophils recovered from the BAL fluid.
CONCLUSION: In our patients leukotrienes and TNF in the BAL fluid correlate well with the acute inflammatory phase of ARDS, as reflected by the increase number of leukocytes in the fluid retrieved, but they do not appear to be clearly predictive index for the syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7808646

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  6 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  The 5-lipoxygenase pathway is required for acute lung injury following hemorrhagic shock.

Authors:  John C Eun; Ernest E Moore; David C Mauchley; Chris A Johnson; Xianzhong Meng; Anirban Banerjee; Max V Wohlauer; Simona Zarini; Miguel A Gijón; Robert C Murphy
Journal:  Shock       Date:  2012-06       Impact factor: 3.454

Review 3.  Anti-TNFα therapy in inflammatory lung diseases.

Authors:  Rama Malaviya; Jeffrey D Laskin; Debra L Laskin
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

Review 4.  Immune response of severely injured patients--influence of surgical intervention and therapeutic impact.

Authors:  S Flohé; S B Flohé; F U Schade; C Waydhas
Journal:  Langenbecks Arch Surg       Date:  2007-06-29       Impact factor: 3.445

5.  Circulating leukotriene B4 identifies respiratory complications after trauma.

Authors:  Birgit Auner; Emanuel V Geiger; Dirk Henrich; Mark Lehnert; Ingo Marzi; Borna Relja
Journal:  Mediators Inflamm       Date:  2012-03-07       Impact factor: 4.711

Review 6.  Serum biomarkers in acute respiratory distress syndrome an ailing prognosticator.

Authors:  Argyris Tzouvelekis; Ioannis Pneumatikos; Demosthenes Bouros
Journal:  Respir Res       Date:  2005-06-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.